Insomnia Agents Claimed 82% of Sales for the Sleeping Disorders Market
Posted on: Monday, 4 September 2006, 12:00 CDT
Research and Markets (http://www.researchandmarkets.com/reports/c41587) has announced the addition of Sleep Disorders: Promotion and Awareness Will Drive Market Growth to their offering.
Sleep disorders affect more than 200 million people worldwide. It is generally accepted that insufficient sleep contributes significantly to automobile accidents and fatalities, work-related injuries, mood depression, and, in general, impaired health. Nevertheless, all sleep disorders are significantly under treated. This level of unmet need presents a significant market opportunity, and sleep disorders increasingly attract the attention of pharmaceutical companies. Additionally, the imminent patent expiration of the blockbuster agent zolpidem (Sanofi-Aventis's Ambien) has attracted the attention of generics manufacturers.
Consequently, the sleep disorders market is likely to experience great change over the next ten years. In this Decision Resources, Inc. report, we focus on the four sleep disorders thought to have major significance for physical and mental health: insomnia, narcolepsy, restless legs syndrome (RLS), and sleep apnea. We examine their etiology and prevalence, current and emerging therapies, the state of the current market, and the outlook for the sleep disorders market in the United States, Europe, and Japan during the period 2005-2015.
Business Implications:
Sleep disorders affect more than 200 million people in the three major market regions we cover. Sales of agents for treatment of the four most significant sleep disorders exceeded $3 billion in 2005, with insomnia agents claiming 82% of the market.
Currently, the insomnia market is dominated by sales of zolpidem (Sanofi-Aventis's Ambien/ Ambien CR). Zolpidem has maintained its position despite the launch of two new agents, eszopiclone (Sepracor's Lunesta) and ramelteon (Takeda's Rozerem). However, we expect sales of zolpidem to peak in 2006 and then decline sharply as a result of generics erosion and the emergence of newer hypnotics.
In 2005, ropinirole (GlaxoSmithKline's Requip) became the first agent to receive approval for treatment of restless legs syndrome (RLS). In the first quarter after approval, sales of ropinirole tripled, based in large part on GSK's extensive awareness campaign. Overall, however, we expect this market to remain small and highly fragmented owing to emerging agents and significant off-label prescribing.
Direct-to-consumer (DTC) advertising and awareness campaigns have a significant impact on the sleep disorders market. Extensive promotion of zolpidem and eszopiclone contributed to strong growth of the insomnia market, and awareness of RLS helped boost the adoption of ropinirole. We expect DTC advertising to continue to play a significant role in the launch of new agents, while sales of ramelteon will be hindered by Takeda's minimal promotion.
Topics Covered
Introduction
Overview of Insomnia
Etiology and Prevalence
Current Therapies
Benzodiazepines
Non-Benzodiazepines
Melatonin Antagonists
Narcolepsy
Etiology and Prevalence
Current Treatments
Restless Legs Syndrome
Etiology and Prevalence
Current Treatments
Sleep Apnea
Etiology and Prevalence
Current Treatments
The Sleep Disorders Market
Emerging Therapies
Insomnia
5-HT2a Antagonists
GABA Agonists
H1 Antagonists
Melatonin Agonists
Narcolepsy
Restless Legs Syndrome
Sleep Apnea
Market Outlook
United States
Europe
Japan
List of Tables:
Table 1:Prevalence of Sleep Disorders, 2005
Table 2:Sales of Leading Agents for the Treatment of Sleep Disorders, 2005
Table 3:Agents in Development for Treatment of Insomnia, 2006
Table 4:Agents in Development for the Treatment of Narcolepsy, Restless Legs Syndrome, and Sleep Apnea
Table 5:Forecasted Sales of Drugs for the Treatment of Sleep Disorders in the Three Major-Market Regions,
2010 and 2015
For more information visit http://www.researchandmarkets.com/reports/c41587
Source: Decision Resources, Inc.
Source: Business Wire
Related Articles
- An Oral Agent for the Treatment of Moderate to Severe Psoriasis Would Earn a Higher Patient Share in the United States than in Europe
- The Russian Food And Drink Market Is Increasing In Sales Value Each Year, Driven By Rising Disposable Income
- Artes Medical Initiates Market Launch and Commercial Sale of Elevess, a New FDA-Approved Hyaluronic Acid-Based Dermal Filler
- 'Biofuels Market in Finland' Report Explores the Current Developments and Market Potential of Biofuels
- Intra-Cellular Therapies Initiates Phase I Clinical Program for Schizophrenia and Sleep Maintenance Disorders
- CORRECTING AND REPLACING IntraOp Medical Announces Record Sales, Expansion into New Markets and Development of Sales Organization
- Cytogen Acquires North American Marketing Rights to CAPHOSOL(R) for Treatment of Both Oral Mucositis and Dry Mouth
- Fonix Accelerates E-Commerce Marketing to Increase Retail Sales
- The Global Market for Sleep-Wake Disorders Currently Estimated at US$4.3 Billion is Forecast to Increase 158% to US$11 Billion By 2012
- Artery disease seen with sleep-breathing disorder
 |
 |
User Comments (0)
RSS Feeds